Celyad Oncology SA (FRA:1C0)

Market Cap	7.83M -61.1%
Revenue (ttm)	186.00K +158.3%
Net Income	-6.46M
EPS	-0.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	91
Open	0.1285
Previous Close	0.1325
Day's Range	0.1285 - 0.1315
52-Week Range	0.1300 - 0.7300
Beta	n/a
RSI	44.15
Earnings Date	Apr 2, 2026

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 19
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1C0

Financial Performance

In 2024, Celyad Oncology's revenue was 186,000, an increase of 82.35% compared to the previous year's 102,000. Losses were -5.82 million, -31.06% less than in 2023.